Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rituximab and autoimmune disorders therapy].

L Quint1

  • 1Service de médecine interne, institut mutualiste-Montsouris, 42 boulevard Jourdan, 75014 Paris, France. laurent.quint@imm.fr

La Revue De Medecine Interne
|October 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[His name could have been Arthur...].

La Revue de medecine interne·2004
Same author

Haemophagocytic syndrome associated with plasmodium vivax infection.

British journal of haematology·2000
Same author

[Polyclonal B lymphocytosis and hyper-IgM: immunodeficiency and/or benign lymphoid proliferation associated with tobacco?].

La Revue de medecine interne·2000
Same author

Mismatch repair and immunoglobulin gene hypermutation: did we learn something?

Immunology today·1999
Same author

[Febrile pancytopenia in the course of AIDS: a hemophagocytic syndrome].

La Revue de medecine interne·1998
Same author

Probing immunoglobulin gene hypermutation with microsatellites suggests a nonreplicative short patch DNA synthesis process.

Immunity·1998

Rituximab, a B-cell depleting therapy, shows promise for treating autoimmune diseases by targeting CD20+ B lymphocytes. Careful consideration of disease-specific pathogenesis is crucial for optimizing its therapeutic efficacy.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Context:

  • B lymphocytes are implicated in the pathogenesis of autoimmune diseases.
  • Targeting B lymphocytes offers a potential therapeutic strategy for autoimmune conditions.

Purpose:

  • To discuss the mechanisms of action of Rituximab, a CD20-directed monoclonal antibody.
  • To explore the implications of Rituximab therapy in managing autoimmune diseases.

Summary:

  • Rituximab effectively depletes CD20-expressing B lymphocytes in vivo.
  • This depletion may eliminate autoantibody-producing B cells, offering a treatment avenue for autoimmune disorders.
  • The discussion covers Rituximab's mechanisms and its potential role in autoimmune disease management.

Related Experiment Videos

Impact:

  • Rituximab presents an attractive therapeutic option for autoimmune disorders due to its B-cell depleting effects.
  • Adapting therapeutic indications to the specific pathogenesis of different autoimmune diseases is essential for maximizing Rituximab's efficiency.